A 10-year follow-up study of participants in the original AREDS trial has been completed. The Age-Related Eye Disease Study Research Group revealed new statistics on the risk and rate of progression from early to advanced age-related macular degeneration (AMD). Participants aged 55 to 80 years with no AMD or AMD of varying severity were followed [Read More]
Category: Latest News
Choroideremia Gene Therapy Showing Promise
Researchers at Oxford University have reported successful findings from their Phase 1/2 clinical testing of the CHM gene for treatment of choroideremia. Choroideremia is a rare disease affecting mostly males that leads to blindness. In the multicentre clinical trial, six male patients (aged 35—63 years) all showed improvement after replacement of the malfunctioning gene. The [Read More]
There’s so much more in life to see
January is National Glaucoma Month The best years are yet to come. With more free time, you can set your sights on wonderful places to go and people to see. Just make sure you keep an eye on glaucoma. Glaucoma is a group of diseases that damages the eye’s optic nerve, which carries visual signals [Read More]
More Reason to Quit Cigarettes
A new study has found further evidence of the risk of cataracts caused by cigarette smoking. A report published January 2, 2014 in JAMA revealed that smoking more than 15 cigarettes per day was associated with a 42% higher likelihood of cataract development compared to those have never smoked. In people who quit smoking for [Read More]
Time Between Lucentis and Eylea Treatments Found To Be Similar
The principal difference between the two leading FDA-approved anti-VEGF drugs, Eylea and Lucentis for treatment of retinal hemorrhage has been accepted as the difference in length of time between injections. A new study, however, found no significant difference in injection scheduling between the drugs. The overall mean days between injections differed by only 1.8 days [Read More]